We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Robert
Horne
r.horne@ucl.ac.uk
Dr Kayonda Hubert
Ngamaba
k.ngamaba@ucl.ac.uk
Rebecca
Todd
b.todd@ucl.ac.uk
Rebecca
Todd
b.todd@ucl.ac.uk
Malignant neoplasms of male genital organs
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
The aim of this research is to better understand differences in outcomes and treatment engagement across white and Black men with prostate cancer. This is because research suggests that Black men are more likely to die from prostate cancer than white men. This project will consist of two phases. The first phase of the project will analyse routinely collected data from men with prostate cancer. Specifically, we will evaluate whether treatment patterns and outcomes differ between men of different ethnicities with prostate cancer, using national datasets. The second phase will explore key perceptions and practicalities influencing treatment engagement and adherence, and those preventing black men from getting the best from treatments particularly for advanced prostate cancer.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Cross-sectional;
You can take part if:
You may not be able to take part if:
Phase 1: Any patients who were diagnosed with prostate cancer outside the defined window of 1st April 2012 and 1st March 2020. Patient with a previous diagnosis of prostate cancer recorded in the cancer registry and those diagnosed after death will also be excluded. Phase 2: Quantitative Observational Study Any patients who do not have capacity to give informed consent. Patients who could not complete a questionnaire in English.
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Rebecca
Todd
b.todd@ucl.ac.uk
Robert
Horne
r.horne@ucl.ac.uk
Rebecca
Todd
b.todd@ucl.ac.uk
Dr Kayonda Hubert
Ngamaba
k.ngamaba@ucl.ac.uk
The study is sponsored by University College London and funded by PROSTATE CANCER RESEARCH .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 60178
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
